ORGANOVO Forum: Community User: Trader_100

Ausblick top

http://globenewswire.com/news-release/2016/06/09/847501/0/en/Organovo-Announces-Fiscal-Fourth-Quarter-and-Full-Year-2016-Results-Company-Issues-Full-Year-Fiscal-2017-Outlook.html

SAN DIEGO, June 09, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NYSE MKT:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today reported financial results for the fiscal fourth quarter of 2016, issued its full-year fiscal 2017 outlook and affirmed its long-range guidance. Net loss was $8.4 million, or $0.09 per share, for the fiscal fourth quarter of 2016, as compared to $7.8 million, or $0.10 per share, for the fiscal fourth quarter of 2015. Organovo reported fiscal fourth-quarter total revenue of $0.5 million, which consisted primarily of collaborations and product and service revenue. Total revenue increased 105 percent versus the comparable period of fiscal 2015 and 67 percent versus the fiscal third quarter of 2016. Collaborations revenue, which primarily represents revenue from the Company’s research agreements with L’Oreal USA and Merck & Co., increased by $0.4 million from the year-ago period. “Fiscal 2016 was a rewarding year for Organovo, as we achieved many of our key operating and scientific targets,” said Keith Murphy, CEO, Organovo. “We issued our outlook today for fiscal 2017 total revenue, which reflects meaningful growth as we drive customer adoption of our liver product and reach important milestones in our research collaborations and partnerships. We also continue to penetrate the global Top 25 pharmaceutical space, having recently added one new customer to bring our total to five with this leading group. Repeat agreements remain strong, as evidenced by the fact that we’re now on a third contract with one of our earliest global Top 25 pharma customers.” Murphy continued, “As we look ahead to fiscal 2017, we’re focused on a few key objectives including accelerated liver tissue revenue growth, initiation of commercial contracting for our kidney product, advancement of our skin model with L’Oreal and sharing preliminary results from our work with multiple tissue types in the therapeutic tissues space. Specifically, we’re moving from functional validation to a customer ‘early-access’ program with our kidney product, and are seeing strong interest from about a dozen potential customers. In all, we’re expanding our product portfolio and diversifying our revenue profile in the preclinical safety and efficacy and disease modeling markets.” Murphy concluded, “Our ability to grow in fiscal 2017 and beyond is rooted in serving attractive and growing markets with critical unmet needs, our leadership position in the 3D bioprinting space and an exceptional IP portfolio around our technology platform and scientific work. We’re poised to change the shape of life science research and transform medical care.” Full-Year Fiscal 2016 Organovo Business Highlights For the full year, Organovo reported net loss of $38.6 million, or $0.43 per share, as compared to net loss of $30.1 million, or $0.38 per share, for fiscal 2015. The Company reported fiscal 2016 total revenue of $1.5 million, which was up 160% from the year-ago period. Total revenue included $0.8 million of product and service revenue and $0.7 million of revenue related to collaborations and grants. Fourth-Quarter Organovo Business Highlights Revenue Product and service revenue was $0.1 million, down 33 percent from the prior-year period, largely driven by the timing of revenue recognition for the Company’s exVive3D Human Liver Tissue research services contracts. As the Company previously stated, certain milestones for revenue recognition from a large customer are expected in early fiscal 2017 rather than late fiscal 2016, reflecting the need for this customer to finalize aspects of its work plan. Collaborations revenue totaled $0.4 million, primarily supported by a milestone achievement from the Company’s agreement with L’Oreal USA to develop the skin tissue model. Operating Expenses Selling, general and administrative expenses decreased 3 percent from the prior-year period to $4.4 million, primarily due to lower employee related costs and non-cash share-based compensation expense. Research and development costs grew 25 percent year-over-year to $4.5 million, reflecting increased employee related costs and lab supplies. Liquidity & Capital Resources The Company ended the fiscal fourth quarter with a cash and cash equivalents balance of $62.1 million. Organovo’s net cash utilization(1) during the period was $7.9 million. The Company’s net cash utilization for the full-year fiscal 2016 was $31.5 million, lower than the expected net cash utilization rate of between $32 million and $34 million. Working capital was $59.2 million to end the fiscal fourth quarter compared to $46.5 million in the prior-year quarter. Fiscal-Year 2017 Outlook The Company issued its full-year fiscal 2017 outlook for total revenue, net cash utilization and initiating of commercial contracting for its kidney tissue product. The Company expects: Total revenue of between $4 million and $6 million for fiscal-year 2017. Fiscal 2016 total revenue was $1.5 million. Net cash utilization of between $32.5 million and $36.5 million for fiscal-year 2017. The Company had a cash and cash equivalents balance of $62.1 million for its fiscal year ended March 31, 2016. Initiation of commercial contracting for its kidney tissue product in the calendar third quarter of 2016. Fiscal-Year 2017 Outlook (June 2016) Fiscal-Year 2017 Total Revenue $4 million - $6 million Net Cash Utilization $32.5 million - $36.5 million Initiation of Commercial Contracting for Kidney Tissue Calendar Third Quarter of 2016 Long-Range Outlook The Company affirmed its long-range outlook for potential revenue from its liver tissue product. The Company continues to expect: As it penetrates the toxicology market, Organovo’s exVive3D Human Liver Tissue and service will grow into the tens of millions in annual revenue, and has $100 million+ revenue potential in the future (inside of a total addressable market of over $1 billion).

Scheinbar. Mal sofort recherchieren

Zahlen waren wohl ganz gut ;-)

Nein. Heute Abend. Spannung steigt. Von den zahlen erwarte ich gar nicht so viel. Entscheidend ist ob es Neuigkeiten zur Forschung gibt, vielleicht tragen die Kooperationen zu ner Überraschung bei

Zahlen schon da?

Ich bin sehr gespannt. Der Kurs lief gut vor Zahlen.

Danke für die News!

California Life Sciences Association Elects Leaders from Merck, Organovo and St. Jude Medical to its Board of Directors Today, California Life Sciences Association (CLSA) announced its board of directors has appointed three new members: Ben Thorner, Vice President, BD&L and Head of North American Innovation Hubs, Merck;Keith Murphy, Chairman and Chief Executive Officer, Organovo; and Dave Anderson, Vice President, Merger & Acquisition Integration, St. Jude Medical. California Life Sciences Association (CLSA) is the nation's largest statewide life sciences public policy advocacy and business solutions organization serving more than 750 biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors and service providers. "We are pleased to welcome these thoughtful leaders from Merck, Organovo and St. Jude Medical to the California Life Sciences Association (CLSA) board of directors," said Sara Radcliffe, President & CEO of California Life Sciences Association (CLSA). "Ben Thorner, Keith Murphy and Dave Anderson will help shape CLSA's agenda and organization goals as we focus on our collective mission of helping grow and foster California's world-leading life sciences sector. These leaders and their respective organizations exemplify the depth and range of CLSA's membership and what we stand for in advancing hope for patients and consumers in California, across our country and around the world."

Zahlen also gg 23 h unserer Zeit und die Auswirkung erst am Do auf den Kurs

Heute wird die 2,7 erklommen...

Live webcast available during our Q4 earnings conference call this Thursday, June 9 at 5pm ET - tune in here: https://t.co/BmUGsCuBK1

Scheint sich so manch einer drauf zu freuen und deckt sich noch ein

Zahlen diese Woche! :)

stimmt...